Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CoLucid Pharmaceuticals has randomized the first patient in its SPARTAN study, the Company’s second Phase 3 pivotal trial of lasmiditan.
Subscribe to our email newsletter
The objective of SPARTAN is to evaluate the safety and efficacy of lasmiditan (50 mg, 100 mg and 200 mg) in comparison to placebo two hours after dosing on freedom from migraine headache pain, which is the primary endpoint, and on freedom from the most bothersome associated symptom of migraine (nausea, phonophobia or photophobia), which is the key secondary endpoint. SPARTAN is a randomized, double-blind, placebo-controlled parallel group study.
The study is expected to treat a single migraine in up to 2,226 migraine patients with lasmiditan at approximately 140 sites in the U.S., United Kingdom and Germany. CoLucid expects migraine patients enrolled in SPARTAN will include those who also have one or more cardiovascular risk factors, stable cardiovascular disease or known coronary artery disease ("CAD").
SPARTAN has been granted a Special Protocol Assessment ("SPA") agreement with the U.S. Food and Drug Agency ("FDA"). Top-line results from SPARTAN are expected in mid-2017.
"We have worked closely with the Division of Neurology Products at FDA to design SPARTAN in a way that we can conduct the trial under SPA agreement. A key differentiator between SPARTAN and our ongoing pivotal Phase 3 clinical trial SAMURAI is that in SPARTAN, we will study a third and lower dose of 50 mg for the acute treatment of migraine," said Thomas P. Mathers, President and Chief Executive Officer of CoLucid.
"The purpose of adding a lower dose is to establish the lowest effective dose of lasmiditan. The 50 mg dose may be particularly effective in lower weight or elderly patients."
About Lasmiditan
Lasmiditan has been designed to be effective in the acute treatment of migraine headaches in adults without the vasoconstrictor activity associated with previous generations of migraine therapies. It selectively targets 5-HT1F receptors expressed in the trigeminal pathway. Lasmiditan has been given the generic stem name "ditan," which distinguishes it from other drug classes, including triptans, the current standard of care for migraine.
CoLucid is currently enrolling patients in SAMURAI, its first of two pivotal Phase 3 clinical trials. The objectives of SAMURAI are to evaluate the safety and efficacy of lasmiditan (100 mg and 200 mg) in comparison to placebo two hours after dosing on freedom from migraine headache pain, which is the primary endpoint, and on freedom from the most bothersome associated symptom of migraine (nausea, phonophobia or photophobia), which is the key secondary endpoint.
SAMURAI is a randomized, double-blind, placebo-controlled parallel group study. The study is expected to treat a single migraine in up to 1,483 migraine patients with lasmiditan at approximately 80 U.S. sites. Patients will include those with migraine who have cardiovascular risk factors or cardiovascular disease. At the enrollment mid-point at least 80% of all migraine patients enrolled in SAMURAI had multiple risk factors for cardiovascular disease. SAMURAI is being conducted under a SPA agreement with the FDA.
Lasmiditan is designed to address major unmet medical needs in migraine patients who are poorly served by currently available therapies, including patients with cardiovascular risk factors or cardiovascular disease that may not be able to take triptans.
CoLucid is also currently enrolling patients in GLADIATOR, a Phase 3 long-term, open-label trial of lasmiditan. GLADIATOR’s objective is to evaluate the safety and efficacy of lasmiditan, as well as resource utilization, functional outcomes and disability. Migraine patients who complete CoLucid’s ongoing first Phase 3 pivotal trial, SAMURAI, as well as the Company’s second Phase 3 pivotal trial, SPARTAN, will be eligible to enroll in GLADIATOR.
GLADIATOR is expected to enroll up to a total of 2,580 subjects, who will be randomized to receive 100 mg or 200 mg of lasmiditan, and treated for up to eight migraine attacks per month for one year. Based on the results of GLADIATOR, CoLucid intends to build an appropriate safety database to support a New Drug Application ("NDA") for lasmiditan. At the time of the NDA submission, it is anticipated that there will be more than 15,000 patient exposures to lasmiditan in the entire clinical program.